Cargando…

Clinical efficacy of Bhringarajasava as Naimittika Rasayana in Rajayakshma with special reference to pulmonary tuberculosis

The clinical study was conducted at the Out Patient Department of State TB Training and Demonstration Centre, S.R. Nagar, Hyderabad, Andhra Pradesh, India, during June 2003 to December 2004. A group of 60 patients of PTB were included in the study and were divided into two equal groups. Both the gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Dornala, Sathya N., Dornala, Snehalatha S.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665204/
https://www.ncbi.nlm.nih.gov/pubmed/23723670
http://dx.doi.org/10.4103/0974-8520.110536
_version_ 1782271228691611648
author Dornala, Sathya N.
Dornala, Snehalatha S.N.
author_facet Dornala, Sathya N.
Dornala, Snehalatha S.N.
author_sort Dornala, Sathya N.
collection PubMed
description The clinical study was conducted at the Out Patient Department of State TB Training and Demonstration Centre, S.R. Nagar, Hyderabad, Andhra Pradesh, India, during June 2003 to December 2004. A group of 60 patients of PTB were included in the study and were divided into two equal groups. Both the groups were on the Directly Observed Treatment Short – course chemotherapy (DOTS) regime. The test group was given DOTS + Bhringarajasava (30 ml thrice a day) and the control group was only on DOTS. The study was to evaluate whether the addition of Bhringarajasava as Naimittika Rasayana (complementary drug) is beneficial in providing faster and better relief or not. Both subjective and objective parameters were considered for the assessment of results. Among the specific symptomatology, Amsaparsabitapah (pain in costal and scapular region), Kasa (cough), Jwara (pyrexia), Swasa (dyspnoea) and Bhaktadwesha (anorexia) were the symptoms manifested by all the patients. Results of the present study indicate that better, safer, and faster relief provided by the addition of Bhringarajasava to DOTS. This is an effort to utilize drugs from the vast Ayurvedic pharmacopoeia as safe adjuvant to DOTS regime so that toxicity and associated side effects of the DOTS can be ameliorated. This process of using therapies from two disparate systems of medicine could potentially lead to further enhancements in the field of complementary medicine and create a symbiosis between the different systems, which may lead to Rasayana DOTS (R-DOTS) in future.
format Online
Article
Text
id pubmed-3665204
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-36652042013-05-30 Clinical efficacy of Bhringarajasava as Naimittika Rasayana in Rajayakshma with special reference to pulmonary tuberculosis Dornala, Sathya N. Dornala, Snehalatha S.N. Ayu Clinical Research The clinical study was conducted at the Out Patient Department of State TB Training and Demonstration Centre, S.R. Nagar, Hyderabad, Andhra Pradesh, India, during June 2003 to December 2004. A group of 60 patients of PTB were included in the study and were divided into two equal groups. Both the groups were on the Directly Observed Treatment Short – course chemotherapy (DOTS) regime. The test group was given DOTS + Bhringarajasava (30 ml thrice a day) and the control group was only on DOTS. The study was to evaluate whether the addition of Bhringarajasava as Naimittika Rasayana (complementary drug) is beneficial in providing faster and better relief or not. Both subjective and objective parameters were considered for the assessment of results. Among the specific symptomatology, Amsaparsabitapah (pain in costal and scapular region), Kasa (cough), Jwara (pyrexia), Swasa (dyspnoea) and Bhaktadwesha (anorexia) were the symptoms manifested by all the patients. Results of the present study indicate that better, safer, and faster relief provided by the addition of Bhringarajasava to DOTS. This is an effort to utilize drugs from the vast Ayurvedic pharmacopoeia as safe adjuvant to DOTS regime so that toxicity and associated side effects of the DOTS can be ameliorated. This process of using therapies from two disparate systems of medicine could potentially lead to further enhancements in the field of complementary medicine and create a symbiosis between the different systems, which may lead to Rasayana DOTS (R-DOTS) in future. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3665204/ /pubmed/23723670 http://dx.doi.org/10.4103/0974-8520.110536 Text en Copyright: © AYU (An International Quarterly Journal of Research in Ayurveda) http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Research
Dornala, Sathya N.
Dornala, Snehalatha S.N.
Clinical efficacy of Bhringarajasava as Naimittika Rasayana in Rajayakshma with special reference to pulmonary tuberculosis
title Clinical efficacy of Bhringarajasava as Naimittika Rasayana in Rajayakshma with special reference to pulmonary tuberculosis
title_full Clinical efficacy of Bhringarajasava as Naimittika Rasayana in Rajayakshma with special reference to pulmonary tuberculosis
title_fullStr Clinical efficacy of Bhringarajasava as Naimittika Rasayana in Rajayakshma with special reference to pulmonary tuberculosis
title_full_unstemmed Clinical efficacy of Bhringarajasava as Naimittika Rasayana in Rajayakshma with special reference to pulmonary tuberculosis
title_short Clinical efficacy of Bhringarajasava as Naimittika Rasayana in Rajayakshma with special reference to pulmonary tuberculosis
title_sort clinical efficacy of bhringarajasava as naimittika rasayana in rajayakshma with special reference to pulmonary tuberculosis
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665204/
https://www.ncbi.nlm.nih.gov/pubmed/23723670
http://dx.doi.org/10.4103/0974-8520.110536
work_keys_str_mv AT dornalasathyan clinicalefficacyofbhringarajasavaasnaimittikarasayanainrajayakshmawithspecialreferencetopulmonarytuberculosis
AT dornalasnehalathasn clinicalefficacyofbhringarajasavaasnaimittikarasayanainrajayakshmawithspecialreferencetopulmonarytuberculosis